SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 3
|
records per page:
next >
| last >>
|
| pages: 1 2 3
|
presentations:
1 to
50 of
102
|
CROI PROGRAM COMMITTEE VICE CHAIR WELCOME TO TUESDAY
Landon Myer
University of Cape Town, Cape Town, South Africa
INTRODUCTION OF JANET SILICIANO
Nicolas Chomont
Université de Montréal, Montréal, Canada
HIV RESERVOIRS: OBSTACLES TO A CURE (ABSTRACT
26)
Janet M Siliciano
The Johns Hopkins University School of Medicine, Baltimore, MD, United States
INTRODUCTION DENISE JAMIESON
Adaora Adimora
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
RESTRICTIONS ON REPRODUCTIVE RIGHTS AND THEIR IMPACT ON PEOPLE LIVING WITH HIV (ABSTRACT
27)
Denise J. Jamieson
Emory University, Decatur, GA, United States
CABOTEGRAVIR PHARMACOLOGY IN THE BACKGROUND OF DELAYED INJECTIONS IN HPTN 084 (ABSTRACT
159)
Mark A. Marzinke
The Johns Hopkins University School of Medicine, Baltimore, MD, United States
THE LEVI SYNDROME: CHARACTERISTICS OF EARLY HIV INFECTION WITH CABOTEGRAVIR FOR PrEP (ABSTRACT
160)
Susan H. Eshleman
The Johns Hopkins University School of Medicine, Baltimore, MD, United States
CABOTEGRAVIR FOR HIV PrEP IN US BLACK MEN AND TRANSGENDER WOMEN WHO HAVE SEX WITH MEN (ABSTRACT
161)
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, United States
CAB LA FOR HIV PREVENTION IN AFRICAN CISGENDER FEMALE ADOLESCENTS (HPTN 084-01) (ABSTRACT
162)
Sybil Hosek
Stroger Hospital of Cook County, Chicago, IL, United States
QUESTIONS AND ANSWERS (Part 1)
Jean-Michel Molina
University of Paris Cité, Paris, France
Valdilea Veloso
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
8+ YEARS POOLED ANALYSIS: ADHERENCE AND HIV INCIDENCE IN 6000 WOMEN ON F/TDF FOR PrEP (ABSTRACT
163)
Jeanne Marrazzo
University of Alabama at Birmingham, Birmingham, AL, United States
SAFETY AND PK/PD OF A TENOFOVIR ALAFENAMIDE/ELVITEGRAVIR INSERT ADMINISTERED RECTALLY (ABSTRACT
164)
Sharon A. Riddler
University of Pittsburgh, Pittsburgh, PA, United States
ULTRA LONG-ACTING REFILLABLE ISLATRAVIR IMPLANT FULLY PROTECTS NHP AGAINST SHIV (ABSTRACT
165)
Alessandro Grattoni
Houston Methodist Research Institute, Houston, TX, United States
QUESTIONS AND ANSWERS (Part 2)
Jean-Michel Molina
University of Paris Cité, Paris, France
Valdilea Veloso
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
INTRODUCTIONS (Part 1)
Judith S. Currier
University of California Los Angeles, Los Angeles, CA, United States
Roger Bedimo
University of Texas Southwestern, Dallas, TX, United States
EFFECTS OF EPLERENONE ON MYOCARDIAL PERFUSION AND FUNCTION: THE MIRACLE HIV STUDY (ABSTRACT
144)
Suman Srinivasa
Massachusetts General Hospital, Boston, MA, United States
DEPRESSION AND ANXIETY ASSOCIATED WITH INCIDENT TYPE I AND II MI AMONG PWH (ABSTRACT
145)
Emily P. Hyle
Harvard Medical School, Boston, MA, United States
WEIGHT AND METABOLIC CHANGES WITH CABOTEGRAVIR+RILPIVIRINE LONG-ACTING OR BICTEGRAVIR (ABSTRACT
146)
Darrell H. S Tan
St Michael's Hospital, Toronto, Canada
A LOSS OF ERa ATTENUATES DTG-MEDIATED DISRUPTION OF THERMOGENESIS IN BROWN ADIPOCYTES (ABSTRACT
147)
Sangwon Kim
The Johns Hopkins University School of Medicine, Baltimore, MD, United States
QUESTIONS AND ANSWERS (Part 1)
Roger Bedimo
University of Texas Southwestern, Dallas, TX, United States
Judith S. Currier
University of California Los Angeles, Los Angeles, CA, United States
MICROBIOTA-DERIVED METABOLITES ARE POWERFUL BIOMARKERS FOR ANAL CANCER PREVENTION (ABSTRACT
148)
Sergio Serrano-Villar
Hospital Ramón y Cajal, Madrid, Spain
IMPACT OF INTEGRASE INHIBITORS ON CARDIOVASCULAR EVENTS IN PERSONS STARTING ART (ABSTRACT
149)
Bernard Surial
University Hospital of Bern, Bern, Switzerland
HIV-RELATED KAPOSI SARCOMA IN EAST AFRICA: CONTEMPORARY UPDATE ON STAGE AND SURVIVAL (ABSTRACT
150)
Helen Byakwaga
Infectious Diseases Institute, Kampala, Uganda
QUESTIONS AND ANSWERS (Part 2)
Roger Bedimo
University of Texas Southwestern, Dallas, TX, United States
Judith S. Currier
University of California Los Angeles, Los Angeles, CA, United States
SPECIAL PRESENTATION: OVERVIEW AND INTRODUCTIONS
Elaine J. Abrams
Columbia University, New York, NY, United States
NEW RECOMMENDATIONS FOR INFANT FEEDING AND PREVENTION OF PEDIATRIC HIV INFECTION IN THE US: WHAT AND WHY NOW?
Judy Levison
Baylor College of Medicine, Houston, TX, United States
INTRODUCTIONS (Part 1)
Andrew Mujugira
Makerere University, Auburn, WA, United States
Connie L. Celum
University of Washington, Seattle, WA, United States
PHYLODYNAMICS OF HIV-1 VARIANT ACROSS POLAND AND UKRAINE (ABSTRACT
151)
Karol Serwin
Pomeranian Medical University, Szczecin, Poland
TIME TO KEY MILESTONES IN THE HIV INDEX TESTING/CONTACT TRACING PATHWAY IN INDIA (ABSTRACT
152)
Parthasarathy Mugundu Ramien
The Johns Hopkins University School of Medicine, Delhi, India
ASSISTED PARTNER SERVICES FOR PWID TO IDENTIFY PARTNERS LIVING WITH HIV & HCV (ABSTRACT
153)
Aliza Monroe-Wise
University of Washington, Seattle, WA, United States
HIV INCIDENCE DIFFERENCES MEASURED BY SERIAL CROSS-SECTIONAL TESTING: HPTN 071 (ABSTRACT
154)
Oliver Laeyendecker
National Institute of Allergy and Infectious Diseases, Baltimore, MD, United States
QUESTIONS AND ANSWERS (Part 1)
Connie L. Celum
University of Washington, Seattle, WA, United States
Andrew Mujugira
Makerere University, Kampala, Uganda
INCIDENCE OF CANCER AMONG MEDICAID BENEFICIARIES WITH AND WITHOUT HIV: 2001-2015 (ABSTRACT
155)
Jacqueline E. Rudolph
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
CAUSES OF DEATH AMONG ADULTS WITH HIV ON ART IN EUROPE AND NORTH AMERICA: 1996-2019 (ABSTRACT
156)
Adam Trickey
University of Bristol, Bristol, United Kingdom
MOLECULAR HIV CLUSTERING OF INDIVIDUALS WITH MPOX/HIV COMORBIDITY (ABSTRACT
157)
Randall Collura
New York State Department of Health, Albany, NY, United States
ISOLATING THE EFFECT OF COVID-19 RELATED DISRUPTION ON HIV DIAGNOSES IN THE US, 2020 (ABSTRACT
158)
Alex Viguerie
Centers for Disease Control and Prevention, Atlanta, GA, United States
QUESTIONS AND ANSWERS (Part 2)
Connie L. Celum
University of Washington, Seattle, WA, United States
Andrew Mujugira
Makerere University, Kampala, Uganda
INTRODUCTIONS (Part 1)
Katharine J. Bar
University of Pennsylvania, Philadelphia, PA, United States
Linos Vandekerckhove
HIV Cure Research Center, Ghent University, Ghent, Belgium
SINGLE-CELL PROTEOGENOMIC PROFILING OF HIV-1 RESERVOIR CELLS (ABSTRACT
135)
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
THE IMPACT OF 3BNC117, 10-1074, AND LEFITOLIMOD ON HIV-1 PERSISTENCE: THE TITAN TRIAL (ABSTRACT
136)
Ole S. Søgaard
Aarhus University Hospital, Aarhus, Denmark
VIRAL AND HOST MEDIATORS OF PERSISTENT LOW-LEVEL VIREMIA (ABSTRACT
137)
Abbas Mohammadi
Brigham and Women's Hospital, Boston, MA, United States
PROVIRUSES IN SELF-REACTIVE CD4+ T CELLS ARE A COMMON SOURCE OF RESIDUAL HIV VIREMIA (ABSTRACT
138)
Fengting Wu
The Johns Hopkins University School of Medicine, Baltimore, MD, United States
QUESTIONS AND ANSWERS (Part 1)
Linos Vandekerckhove
HIV Cure Research Center, Ghent University, Ghent, Belgium
Katharine J. Bar
University of Pennsylvania, Philadelphia, PA, United States
EX VIVO HIV DNA INTEGRATION IN STAT3 DRIVES T CELL PERSISTENCE AND OVERGROWTH (ABSTRACT
139)
Michael Rist
Tufts University, Boston, MA, United States
THERAPEUTIC VACCINATION OF SHIV-INFECTED, ART-SUPPRESSED INFANT RHESUS MACAQUES (ABSTRACT
140)
Bhrugu Yagnik
Emory Vaccine Center, Atlanta, GA, United States
VIRAL RESERVOIR LANDSCAPE OF CHILDREN WITH HIV IN BOTSWANA TREATED WITH DUAL bNAbs (ABSTRACT
141)
Aischa Niesar
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
SINGLE-CELL EPIGENETIC, TRANSCRIPTIONAL, AND PROTEIN STATES OF HIV RESERVOIR (ABSTRACT
142)
Yulong Wei
Yale University, New Haven, CT, United States
ANTI-IL-10/PD-1 IMMUNE MEDIATED CONTROL OF VIRAL REBOUND IN SIV INFECTED MACAQUES (ABSTRACT
143)
Susan Pereira Ribeiro
Emory University, Atlanta, GA, United States
QUESTIONS AND ANSWERS (Part 2)
Linos Vandekerckhove
HIV Cure Research Center, Ghent University, Ghent, Belgium
Katharine J. Bar
University of Pennsylvania, Philadelphia, PA, United States
ENSITRELVIR FOR MILD-TO-MODERATE COVID-19: PHASE 3 PART OF PHASE 2/3 STUDY (ABSTRACT
166)
Takeki Uehara
Shionogi & Co., Ltd., Osaka, Japan
|
<< first | < prev
page:
of 3
|
records per page:
next >
| last >>
|
| pages: 1 2 3
|
presentations:
1 to
50 of
102
|
